PR
AVBP icon

PSP Research’s ArriVent BioPharma AVBP Stock Holding History

PSP Research’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$245K Buy
+7,041
New +$208K 0.13% 59

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PSP Research's AVBP Position: Q2 2026 in Review

PSP Research opened a new position in ArriVent BioPharma (AVBP) in Q2 2026: 7,041 shares worth $245K. The stake represents 0.13% of the portfolio and ranks #59 among its holdings.

157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • PSP Research held 7,041 shares of ArriVent BioPharma worth $245K as of Q2 2026.
  • ArriVent BioPharma was a new PSP Research position in Q2 2026.
  • ArriVent BioPharma made up 0.13% of PSP Research's portfolio in Q2 2026, its #59 holding.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.